The Capital Stack

Three founding investments define the modern longevity capital stack. Calico Labs was established in 2013 as a subsidiary of what became Alphabet, Inc., with Art Levinson — then chairman of both Apple and Genentech — installed as CEO. The company was a personal project of Google co-founders Larry Page and Sergey Brin. Total investment is estimated at over $1 billion, though exact figures are difficult to establish because Calico has been described by industry observers and journalists as unusually opaque about its research directions, publication record, and internal priorities. For a company of its scale and stated ambition — to understand the biology of aging and develop interventions — its public output has been notably sparse relative to its funding.

Altos Labs launched in January 2022 with $3 billion in initial financing, making it the largest biotech startup founding in history by a wide margin. Its backers include Jeff Bezos and the Russian-Israeli billionaire Yuri Milner. The company recruited Nobel laureate Shinya Yamanaka, discoverer of the cell reprogramming factors that bear his name, and assembled over 150 scientists across research institutes in the San Francisco Bay Area, San Diego, Cambridge (UK), and Japan. In 2025, Altos appointed its first Chief Medical Officer — a structural signal, in biotech convention, that a company is preparing to move from basic research into human clinical trials. The company's stated focus is cellular rejuvenation programming.

Retro Biosciences, founded in 2021, represents a different capital structure: a $180 million personal investment from Sam Altman, CEO of OpenAI. The company's research targets include cellular reprogramming, autophagy (the body's mechanism for clearing damaged cellular components), and plasma-inspired therapies. In scale, Retro is an order of magnitude smaller than Altos. In structure, it is notable as a direct personal deployment of wealth by the individual widely regarded as the central figure in commercial artificial intelligence — a fact that positions him at the intersection of two of the decade's defining technology investment categories.

These three entities — Calico, Altos, Retro — did not emerge from pharmaceutical industry R&D pipelines, academic grant structures, or government health agencies. They emerged from the personal wealth and direct decisions of technology billionaires. This is the founding condition of the field's capital architecture, and it has consequences that the remainder of this paper documents.

Alongside institutional capital deployment, a parallel pattern has emerged: individual ultra-high-net-worth actors funding longevity research through personal foundations, direct grants, or self-experimentation. Larry Ellison, co-founder and former CEO of Oracle Corporation, established the Ellison Medical Foundation, which distributed approximately $430 million in aging research grants between 1997 and 2013 before closing. The foundation was for its duration one of the largest non-governmental funders of aging biology in the world. Its closure did not reflect disillusionment with the science; Ellison has continued to make personal statements about his intent to live significantly longer than the actuarial norm.

Peter Thiel, co-founder of PayPal and Palantir Technologies, has funded longevity research through multiple vehicles: the Methuselah Foundation, the SENS Research Foundation (which funds damage-repair approaches to aging), and direct investment in companies such as Unity Biotechnology, a senolytic drug developer. Thiel has publicly discussed his interest in parabiosis research — the use of young blood factors documented in LG-001 — and has been a consistent public advocate for treating aging as an engineering problem rather than an inevitability.

The most publicly documented individual protocol belongs to Bryan Johnson, a technology entrepreneur who sold his payments company Braintree to PayPal for $800 million in 2013. Johnson's Blueprint protocol, which costs approximately $2 million per year, subjects his body to a comprehensive regimen of supplements, pharmaceuticals, diet, exercise, and monitoring, with every biomarker tracked and the full protocol published online. It is the most extensively documented self-experimentation program in the longevity field. Johnson also conducted a generational plasma exchange with his then-17-year-old son — a procedure he publicly discontinued after his team found no measurable evidence of benefit, a disclosure that itself distinguished the project from less transparent efforts in the space.

These individual actors are not marginal figures. They are among the wealthiest people in the history of the species. Their personal biological interests — survival, health extension, age reversal — are now directly expressed as capital allocation decisions that shape the research agenda of an entire scientific domain. The question is not whether their interests are understandable. The question is what happens to a field's research priorities when its funding structure is this concentrated.

The capital deployed by billionaire founders and individual patrons does not exist in isolation. It sits atop a commercial market that has already reached significant scale. Grand View Research and Allied Market Research estimated the global anti-aging market at $191 billion in 2023, with projections reaching $421 billion by 2030. The broader longevity sector — encompassing diagnostics, therapeutics, wellness, supplements, and clinical services — is projected by multiple industry analyses to exceed $1 trillion in total value by the mid-2030s. These figures include everything from retinol creams to gene therapy, but the trajectory is clear: longevity has become one of the largest addressable markets in healthcare.

At the high end, commercial clinics have already begun offering interventions derived from the science documented in LG-001. Ambrosia, a startup founded in 2016, charged $8,000 per liter for young plasma transfusions before the FDA issued a warning in 2019 stating that the procedure had no proven clinical benefit and carried known risks. The Maharaj Institute in Florida offers a treatment course priced at $285,000, as reported by STAT News. These prices establish the current access architecture for early-stage longevity interventions: they are available now, at price points that restrict access to the wealthy, and without the regulatory validation that would be required for insurance coverage or public health deployment.

A structural analogy is instructive. GLP-1 receptor agonists — the class that includes semaglutide (Ozempic/Wegovy) — transformed weight management from a domain defined by surgical intervention and lifestyle advice into a pharmaceutical market with a cost curve that, while still high, is declining as production scales and patents approach expiration. The longevity field may follow a similar trajectory: interventions that begin as bespoke, expensive, and minimally regulated may eventually move toward pharmaceutical standardization, regulatory approval, and broader accessibility. But the timeline matters. If commercially available age-reversal therapies remain at six-figure price points for 10 to 15 years before cost declines, the distributional consequences during that window are substantial.

The market architecture, in other words, is not simply large. It is structured so that the earliest beneficiaries are, by definition, those who can pay the most — and those who can pay the most are, in many cases, the same individuals whose capital funded the underlying research.

Three structural features define the investment architecture documented above. The first is concentration. A small number of individuals — countable on two hands — hold the majority of private capital deployed in fundamental longevity science. Bezos, Milner, Altman, Brin, Page, Ellison, Thiel, Johnson. Their combined direct investment exceeds $5 billion. Their biological interests, life stage, and personal convictions about the tractability of aging are the primary drivers of which research questions receive the most funding. This is not unique to longevity — pharmaceutical investment has always reflected the interests of its funders — but the degree of concentration is unusual even by the standards of biotech venture capital.

The second feature is secrecy. Calico Labs, despite operating for over a decade with billion-dollar-plus backing from the world's fourth-largest company by market capitalization, has published comparatively little and disclosed even less about its internal research priorities. This opacity is not illegal. It is standard practice for corporate R&D. But in a field with direct public-health implications, information asymmetry between those deploying capital and the public whose health is at stake creates a structural condition: the people best positioned to know what works are also the people best positioned to benefit first from that knowledge.

The third feature is timeline. Altos Labs and Calico operate on 5-to-10-year research horizons, consistent with the pace of biotech drug development from basic science through clinical trials to commercial availability. The investors who founded and funded these companies in their 40s, 50s, and 60s will be in their 50s, 60s, 70s, and 80s when the first therapies reach the market. This is the age window in which biological age reversal is most personally consequential — the interval during which the difference between a biological age of 55 and a biological age of 70 translates directly into functional capacity, disease risk, and life expectancy. The alignment between investment timeline and personal biological need is not incidental. It is the defining structural feature of the capital stack.

The capital stack does not make the science less real. LG-001 documented the peer-reviewed evidence for heterochronic parabiosis, senolytics, and epigenetic reprogramming. That evidence stands on its own methodological merits, independent of who funds it. Yamanaka factors do not become less effective because Jeff Bezos pays the salary of the scientist who discovered them. Senolytic clearance of damaged cells does not become less measurable because Peter Thiel invested in a company pursuing it. The science is the science.

What the capital stack determines is everything else. It determines who benefits first — the investors and their immediate networks, who will have access to therapies years before regulatory approval and insurance coverage make them broadly available. It determines who has access at what price — the current range of $8,000 to $285,000 per treatment course establishes a baseline that will decline over time but will remain exclusionary for years or decades. It determines what research questions are prioritized — the questions most relevant to the biological concerns of wealthy men in their 50s through 70s, rather than the questions most relevant to global disease burden, health equity, or the aging patterns of populations without access to concierge medicine.

This is the same structural question the ICS corpus documents in pharmaceutical capture (the WI series), knowledge enclosure (the KA series), and every other domain where large-scale capital investment shapes a field with direct public-health implications. The pattern is consistent: when private capital concentrates in a domain that affects public health, the resulting distribution of benefits reflects the interests of the capital holders, not the needs of the population. The mechanism is not conspiracy. It is structure. Capital flows toward the problems its holders want solved, on the timelines that serve their interests, at price points that reflect their willingness to pay.

The distributional outcome — who gets access to biological age reversal, when, and at what cost — is not a side effect of the investment architecture. It is the primary structural product of concentrating research funding in the hands of those with the most personal interest in the outcome. The subsequent papers in this series (LG-003 through LG-008) document the access architecture, regulatory landscape, and public-health implications that follow from the capital stack described here.